💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, fairly priced.
Zydus Lifesciences is scored on the pharma / healthcare framework. It keeps a healthy 18.2% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.42×) — worth a closer look. Free cash flow is worth about -5.2% of its market value.
Over the last 3 years revenue compounded at 17%/yr and profit at 36%/yr. Book value has grown 15%/yr. Return on equity is a healthy 15.1%. In the latest quarter profit fell 29% versus the prior quarter.
At 24× earnings, the stock sits at the 47th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~13%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 27.71 | — | — |
| P/B | 4.29 | 4.1 | worse |
| EV/EBITDA | 15.94 | 19.33 | better |
| ROE | 15.1 | — | — |
| ROCE | 14.86 | 14.41 | better |
| ROA | 7.63 | 1.64 | better |
| Quick Ratio | 0.91 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 17% CAGR over 3 years — steady double-digit compounder.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (36% vs 17%) — margin expansion is at work.
Operating margin has expanded from 15% to 24% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 17% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 7pp across the window.
EPS has grown every year — each share earns more than the last, consistently. 37% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 0.4× PAT — reported profit isn't translating into cash, raising earnings quality questions. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 5% sequentially — momentum is building. Run-rate stepping up — recent quarters average 20% above earlier ones.
Profit fell 29% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (20% → 12%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 75.0% — heavily owner-operated with strong skin in the game. MF holding up 2.2pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.